Recombinant Human Endorepellin Protein, CF

When Recombinant Human VEGFR1/Flt-1 Fc Chimera (Catalog # 321-FL) is immobilized at 5 μg/mL (100 μL/well), Recombinant Human Endorepellin/Perlecan (Catalog # 2364-ER) binds with an ED50 of 0.75-6 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Endorepellin Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human VEGF R1/Flt-1 (Catalog # 321-FL) is coated at 5 μg/mL (100 μL/well), the concentration of Recombinant Human Endorepellin/Perlecan that produces 50% of the optimal binding response is approximately 0.75-6 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived human Endorepellin/Perlecan protein
  Arg3684-Ser4391 (Ser4004Thr), with a C-terminal 10-His tag
• Accession #: P98160
• N-terminal Sequence: Arg3684
• Protein/Peptide Type: Recombinant Proteins
• Gene: HSPG2
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 76.7 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 90-95 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Endorepellin Protein, CF

• basement membrane-specific heparan sulfate proteoglycan core protein
• endorepellin (domain V region)
• heparan sulfate proteoglycan 2
• Heparan Sulfate Proteoglycan
• HSPG
• perlecan proteoglycan
• perlecan
• PLCSchwartz-Jampel syndrome 1 (chondrodystrophic myotonia)
• PRCAN
• SJA
• SJS
• SJS1

Background

Endorepellin is an 80 kDa glycoprotein that is derived from the C-terminal end of the heparan sulfate proteoglycan, Perlecan. Perlecan itself is an approximately 850 kDa modular protein that contains multiple LDLR, EGF-like, Laminin-like, and immunoglobulin-like domains. Mouse Perlecan lacks several of the Ig-like domains found in the human protein (1-3). Endorepellin corresponds to domain V of Perlecan and consists of three Laminin G domains separated by four EGF-like domains (4). Human Endorepellin shares 89% amino acid sequence identity with mouse Endorepellin. A 26 kDa fragment of Endorepellin is known as LG3 and contains the third Laminin G-like domain of Endorepellin. LG3 can be released by Cathepsin L or BMP-1/Tolloid family mediated cleavage (4-6). Endorepellin binds to Integrin alpha 2/ beta 1, preventing the integrin-dependent adhesion of vascular endothelial cells (EC) to fibronectin and collagen I (7, 8). In contrast, this interaction enhances platelet adhesion to collagen as well as platelet aggregation and activation (9). Endorepellin additionally binds to VEGF R1 and VEGF R2 on EC (10). Its binding to VEGF R2 and Integrin alpha 2/ beta 1 on EC induces the association and down‑regulation of both proteins, followed by the inhibition of EC migration, tubulogenesis, secretion of VEGF, and the activation of multiple receptors involved in angiogenesis (4, 7, 8, 10, 11). Endorepellin also binds to Endostatin, resulting in a reduction of the anti-angiogenic activity of both proteins (4). It preferentially interacts with tumor vasculature and inhibits tumor growth and angiogenesis (8, 12).

1. Whitelock, J.M. et al. (2008) Biochemistry 47:11174.
2. Murdoch, A.D. et al. (1992) J. Biol. Chem. 267:8544.
3. Noonan, D.M. et al. (1991) J. Biol. Chem. 266:22939.
4. Mongiat, M. et al. (2003) J. Biol. Chem. 278:4238.
5. Cailhier, J.-F. et al. (2008) J. Biol. Chem. 283:27220.
6. Gonzalez, E.M. et al. (2005) J. Biol. Chem. 280:7080.
7. Bix, G. et al. (2004) J. Cell Biol. 166:97.
8. Woodall, B.P. et al. (2008) J. Biol. Chem. 283:2335.
9. Bix, G. et al. (2007) Blood 109:3745.
10. Goyal, A. et al. (2011) J. Biol. Chem. 286:25947.
11. Nystrom, A. et al. (2009) Blood 114:4897.
12. Bix, G. et al. (2006) J. Natl. Cancer Inst. 98:1634.

Publications for Endorepellin/Perlecan/Heparan Sulfate Proteoglycan (2364-ER)(3)

Publications using 2364-ER

• Provenzale, I;De Simone, I;Gibbins, JM;Heemskerk, JWM;van der Meijden, PEJ;Jones, CI; Regulation of Glycoprotein VI-Dependent Platelet Activation and Thrombus Formation by Heparan Sulfate Proteoglycan Perlecan International journal of molecular sciences 2023-08-28 [PMID: 37686158] (Bioassay, Human)
• ME Katt, RM Linville, LN Mayo, ZS Xu, PC Searson Functional brain-specific microvessels from iPSC-derived human brain microvascular endothelial cells: the role of matrix composition on monolayer formation Fluids Barriers CNS, 2018-02-20;15(1):7. 2018-02-20 [PMID: 29463314] (Bioassay, Human)
• The Different Binding Properties of Cultured Human Corneal Endothelial Cell Subpopulations to Descemet&#039;s Membrane Components Invest Ophthalmol Vis Sci, 2016-09-01;57(11):4599-605. 2016-09-01 [PMID: 27598865] (Bioassay, Human)

Bioinformatics

• Gene Symbol: HSPG2
• Uniprot:
  • P98160()